Summary
Thermo Fisher Scientific Inc. (TMO) reported its third-quarter results for the period ending September 30, 2005, showing a robust 25% year-over-year revenue increase driven significantly by strategic acquisitions, most notably the acquisition of the Kendro Laboratory Products division. While revenues grew, operating income margin saw a slight decrease from 11.0% to 9.1%, primarily due to increased amortization of acquisition-related intangible assets and higher restructuring costs associated with integrating new businesses. The company continues to actively manage its portfolio through acquisitions and divestitures, demonstrated by the sale of its point-of-care and rapid diagnostics business. Financially, the company saw a decrease in net income to $57.7 million from $106.5 million in the prior year's quarter, impacted by higher interest expenses and an increased effective tax rate. Cash flow from operations for the nine-month period also declined compared to the previous year, largely due to increased investment in working capital. Despite these factors, TMO affirmed its belief that its current liquidity, operational cash flow, and available credit facilities are sufficient to meet its capital needs for the foreseeable future.
Key Highlights
- 1Revenue grew 25% year-over-year to $679.4 million in Q3 2005, driven by acquisitions, including the significant Kendro acquisition.
- 2Operating income margin decreased to 9.1% from 11.0% year-over-year, primarily due to higher amortization of acquisition-related intangibles and restructuring costs.
- 3Net income for the quarter decreased to $57.7 million from $106.5 million in Q3 2004, impacted by higher interest expense and an increased tax rate.
- 4The company completed multiple acquisitions in 2005, including Kendro, Niton, Rupprecht and Patashnick (R&P), and Ionalytics, significantly expanding its business scope.
- 5Cash flow from operations for the first nine months of 2005 was $144.9 million, down from $175.7 million in the same period of 2004, mainly due to working capital investments.
- 6Thermo Fisher Scientific sold its point-of-care and rapid diagnostics business in Q3 2005, generating an after-tax gain of $17.1 million.
- 7The company maintains a strong balance sheet with total debt of $639.5 million at October 1, 2005, and believes its liquidity is sufficient for at least the next 24 months.